학술논문

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Document Type
Article
Source
In: The Lancet Oncology. (The Lancet Oncology, April 2024, 25(4):439-454)
Subject
Language
English
ISSN
14745488
14702045